Aurora Cannabis (ACB) Q2 2027 earnings summary

Executive summary

• Q2 FY27 net revenue rose 9% YoY to $86.0M; record international medical cannabis revenue of $61.4M grew 44% YoY.

• Adjusted EBITDA was $14.0M; continuing-operations net loss narrowed to $21.1M from $27.2M, while adjusted net income fell to $3.1M from $12.0M.

Financial highlights

• Net revenue was $86.0M vs. $78.8M YoY; gross profit was $37.5M vs. $31.1M, and adjusted gross profit before fair value adjustments was $52.3M vs. $51.2M.

• Adjusted EBITDA was $14.0M vs. $15.4M YoY; adjusted SG&A rose to $37.4M from $34.9M.

• Operating expenses rose to $55.5M from $48.2M YoY.

• Free cash flow outflow improved to $17.5M from $39.9M YoY, primarily reflecting working capital investment of $12.6M vs. $37.2M.

Outlook and guidance

• The proposed Organigram transaction is expected to close in January 2027, subject to shareholder, court and regulatory approvals and customary closing conditions; a shareholder meeting is expected in December 2026.